Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05189938
Other study ID # ADC-US-RES-21212
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date December 20, 2021
Est. completion date June 2024

Study information

Verified date January 2024
Source Abbott Diabetes Care
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To evaluate the relationship between glycated hemoglobin (HbA1c) and average glucose levels using continuous glucose monitoring.


Description:

This is a non-pivotal , non-randomized, single-arm, multi-center, prospective, non-significant risk study to evaluate the relationship between glycated hemoglobin (HbA1c) and average glucose levels. Up to approximately 600 subjects will be enrolled who will have fourteen (14) study visits over the course of approximately six (6) months. During each visit the subject will have blood samples drawn for documentation of their HbA1c level. Subjects will also be required to wear Professional FreeStyle Libre Flash Glucose Monitoring System(s) to record blood glucose levels through the duration of the study. During Visits 1 and 14, Venous sample for CBC, biochemistry, haemoglobinopathy screen, hematology, liver function and iron panels will be collected.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 600
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 4 Years and older
Eligibility Inclusion Criteria: 1. Subject must have type 1 or type 2 diabetes. 2. Subject is at least 4 years old. 3. Point-of-care (POC) HbA1C of 3.0%-15.5% (9 mmol/mol - 146 mmol/mol) 4. Subject must be able to read and understand English. 5. In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol. 6. Subject must be available to participate in all study visits. 7. Subject must be willing and able to provide written signed and dated informed consent. 8. Subjects age 4 - 17: Parent or guardian must be willing and able to provide written signed and dated informed consent. 9. Subjects age 11 - 17 Subject must be willing and able to provide written signed and dated informed assent. Exclusion Criteria: 10. Subject is currently undergoing dialysis or planning to receive dialysis during the course of the study 11. History of blood transfusion in the last 3 months or planned blood transfusion during the course of the study. 12. Subject is currently planning to undergo a major medical intervention expected to significantly alter red cell life span, i.e. chemotherapy, major surgery requiring blood transfusions, etc. 13. Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin. 14. Subjects age 18 and older: Subject is known to be pregnant, attempting to conceive or is not willing and able to practice birth control during the study duration study (applicable to female subjects only). Subjects age 17 and younger: Subject is known to be pregnant at the time of study enrollment or is planning to become pregnant during the study (applicable to female subjects only). 15. Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema. 16. Subject has a pacemaker or any other neurostimulators. 17. Subject has concomitant medical condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the subject or study staff. 18. Subject is currently participating in another interventional clinical trial. 19. Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
HBA1c data and glucose levels
All subjects will wear the professional FreeStyle Libre Pro for glucose data and HbA1c data will be collected at different time points over the participation period.

Locations

Country Name City State
United Kingdom University Hospital Birmingham Birmingham
United Kingdom Bradford Royal Infirmary Bradford
United Kingdom Royal Derby Hospital Derby
United Kingdom Edinburgh Royal Infirmary Edinburgh
United Kingdom Northwick Park Hospital Harrow
United Kingdom Hull Royal Infirmary Hull
United Kingdom St James University Hospital Leeds
United Kingdom Leicester General Hospital Leicester
United Kingdom Manchester Royal Infirmary Manchester
United Kingdom Nottingham Children's Hospital & Queen's Medical Centre Nottingham
United Kingdom Royal Berkshire Hospital Reading
United Kingdom Northern General Hospital Sheffield
United Kingdom Ealing Hospital Southall
United Kingdom The Royal London Hospital Whitechapel
United States Billings Clinic Billings Montana
United States Eastside Research Associates Redmond Washington

Sponsors (1)

Lead Sponsor Collaborator
Abbott Diabetes Care

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Establish a relationship between laboratory-derived HbA1c and average glucose levels This is an observational data collection study, where the goal is to gather data to establish the relationship between laboratory-derived HbA1c and average glucose levels. six (6) months
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A